Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

医学 内科学 中止 髓系白血病 耐受性 人口 不利影响 耐火材料(行星科学) 临床研究阶段 肿瘤科 胃肠病学 临床试验 天体生物学 物理 环境卫生
作者
Martha Lucia Arellano,Michael J. Thirman,John F. DiPersio,Maël Heiblig,Eytan M. Stein,Andre C. Schuh,Andrius Žučenka,Stéphane de Botton,Carolyn S. Grove,Gabriel N. Mannis,Cristina Papayannidis,Alexander E. Perl,Ghayas C. Issa,Ibrahim Taha Aldoss,Ashish R. Bajel,David S. Dickens,Michael W.M. Kühn,Ioannis Mantzaris,Emmanuel Raffoux,Elie A. Traer
出处
期刊:Blood [Elsevier BV]
卷期号:146 (9): 1065-1077 被引量:110
标识
DOI:10.1182/blood.2025028357
摘要

ABSTRACT: The prognosis for relapsed or refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML) is poor and represents an urgent unmet medical need. Revumenib, a potent, selective menin inhibitor, was recently approved for the treatment of R/R acute leukemia with a KMT2A translocation in patients aged ≥1 year based on results from the phase 1/2 AUGMENT-101 study. Here, we present results from patients with R/R NPM1m AML enrolled in the phase 2 portion of AUGMENT-101. Enrolled patients received revumenib with or without a strong CYP3A4 inhibitor every 12 hours in 28-day cycles. Primary end points were rate of complete remission (CR) or CR with partial hematologic recovery (CRh; CR + CRh), safety, and tolerability. Secondary end points included overall response rate (ORR) and duration of response. As of 18 September 2024, 84 patients received ≥1 dose of revumenib. Median age was 63 years; 1 patient was aged <18 years. The protocol-defined, efficacy-evaluable population for the primary analysis included 64 adult patients (≥3 previous lines of therapy, 35.9%; previous venetoclax, 75.0%). The CR + CRh rate was 23.4% (1-sided P = .0014); the ORR was 46.9%. Median duration of CR + CRh was 4.7 months. Of 30 responders, 5 (16.7%) proceeded to hematopoietic stem cell transplant (HSCT) and 3 resumed revumenib after HSCT. Treatment-related adverse events led to treatment discontinuation in 4 patients (4.8%). Revumenib demonstrated clinically meaningful responses in this heavily pretreated, older population with NPM1m AML, including remissions that enabled HSCT. The safety profile of revumenib was consistent with previously reported results. This trial was registered at www.clinicaltrials.gov as #NCT04065399.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
诚心的香水完成签到,获得积分10
刚刚
赫江涛发布了新的文献求助30
刚刚
1秒前
大模型的应助被夏夏采纳,获得10
1秒前
aaa发布了新的文献求助10
1秒前
866发布了新的文献求助10
2秒前
2秒前
风吹麦浪发布了新的文献求助50
3秒前
4秒前
笑点低的从菡完成签到,获得积分10
4秒前
smile发布了新的文献求助10
4秒前
yyf完成签到 ,获得积分10
5秒前
5秒前
Seorina发布了新的文献求助10
6秒前
6秒前
哇爱学习发布了新的文献求助10
6秒前
wendy完成签到,获得积分10
7秒前
7秒前
1717完成签到,获得积分10
7秒前
自由自在完成签到,获得积分10
7秒前
7秒前
9秒前
9秒前
xl发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
10秒前
LPH01完成签到,获得积分10
10秒前
虚幻的冬瓜完成签到,获得积分10
11秒前
ZZt完成签到,获得积分10
11秒前
子衿完成签到 ,获得积分10
11秒前
11秒前
无花果的应助被Seorina采纳,获得10
11秒前
宝宝完成签到,获得积分10
12秒前
GIN的应助被myuniv采纳,获得10
13秒前
何钦发布了新的文献求助10
13秒前
taik发布了新的文献求助10
14秒前
彭于晏的应助被1717采纳,获得10
14秒前
清脆凤发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192903
求助须知:如何正确求助?哪些是违规求助? 9579346
关于积分的说明 21864636
捐赠科研通 7792529
什么是DOI,文献DOI怎么找? 3437107
关于科研通互助平台的介绍 2560653
邀请新用户注册赠送积分活动 2483937